66th Annual Meeting of the Japanese Society of Neurology
Advanced Search

Session Details

Japanese Poster Session

[Pj-096]Japanese Poster Session 096　Neuroimmunology (NMO 3)

Sat. May 24, 2025 1:30 PM - 2:50 PM JST
Sat. May 24, 2025 4:30 AM - 5:50 AM UTC
ポスター会場(大阪国際会議場3F イベントホール)
Chair: Kenzo Sakurai（St. Marianna University School of Medicine, Japan）

[Pj-096-1]Clinical characteristics of eleven cases with satralizumab-extended interval dosing in NMOSD

Katsuhisa Masaki, Hajime Takeuchi, Ayano Matsuyoshi, Keisuke Mizutani, Yuuichi Kira, Kazunori Iwao, Koji Shinoda, Mitsuru Watanabe, Noriko Isobe (Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Japan)

[Pj-096-2]Clinical analysis of patients with neuromyelitis optica spectrum disorder treated with satralizumab

Masashi Kino1,2, Kazushi Deguchi2, Jun Kurimoto2, Keita Takaba2, Makoto Kita2, Kisaki Tachi2, Rie Kawakita2, Hideki Kobara2 (1.Kagawa University School of Medicine, Municipal Hospital Support and Promotion Medicine, Japan, 2.Kagawa University Hospital, Department of Gastroenterology and Neurology, Japan)

[Pj-096-3]clinical characteristics of anti AQP4 antibody positive NMOSD introduced with biological agents

Takahiro Nose, Takeshi Kuroda, Yumika Kokudai, Daiki Shoji, Ayako Miki, Ken Yamamoto, Naohito Ito, Natsuko Iizuka, Mizuki Kanemoto, Hidetomo Murakami (Department of Neurology, Showa University Faculty of Medicine, Japan)

[Pj-096-4]Seven cases of hyperCKemia in the acute phase of anti-AQP4 antibody-positive NMOSD

Tatsuhiko Sano1, Yoichiro Nishida1, Takanori Yokota1,2 (1.Department of Neurology and Neurological Science, Institute of Science Tokyo, Japan, 2.NucleoTIDE and PepTIDE Drug Discovery Center, Institute of Science Tokyo, Japan)

[Pj-096-5]To explore the changes in GFAP and NfL concentrations in patients with AQP4-positive NMOSD

Itsuki Sano, Naoshi Koizumi, Ryohei Yamamura, Toru Koda, Makoto Kinoshita, Tatsusada Okuno, Hideki Mochizuki (Department of Neurology, Graduate School of Medicine, Osaka University, Japan)

[Pj-096-6]Benefit Assessment of the Patient Support Program "Circle" in NMOSD patients using satralizumab

Yuta Kamei1, Chiaki Sugita1, Katsuhisa Yamashita2, Kazuo Fujihara3,4 (1.Drug Safety Division, Chugai Pharmaceutical Co., Ltd., Japan, 2.Medical Affairs Division, Chugai Pharmaceutical Co. Ltd., Japan, 3.Multiple Sclerosis and Neuromyelitis Optica Center, Southern TOHOKU Research Institute for Neuroscience, Japan, 4.Department of Multiple Sclerosis Therapeutics, Fukushima Medical University School of Medicine, Japan)
Back to Category List